Conference Coverage

AAGP: Treating Parkinson’s psychosis takes balance on risk/benefit tightrope


 

EXPERT ANALYSIS FROM THE AAGP ANNUAL MEETING

References

The drug also is being investigated for Alzheimer’s disease psychosis.

Dr. Marsh disclosed that she had received honoraria from Roche Pharmaceuticals in 2013, and has received royalties from Taylor & Francis/Informa.

msullivan@frontlinemedcom.com

On Twitter @alz_gal

Pages

Recommended Reading

Pseudobulbar affect: More common than you’d think
MDedge Family Medicine
Rasagiline’s failure as active control halts phase III preladenant trial
MDedge Family Medicine
VIDEO: Bottom line on maternal infections and cerebral palsy
MDedge Family Medicine
Aerobic walking beneficial in patients with mild to moderate Parkinson’s
MDedge Family Medicine
Dopamine receptor agonists trigger impulse control disorders
MDedge Family Medicine
Extended-release carbidopa-levodopa approved for Parkinson’s
MDedge Family Medicine
Intestinal carbidopa-levodopa gets FDA approval
MDedge Family Medicine
Pathologic proteins in Alzheimer’s, Parkinson’s also collect in skin cells
MDedge Family Medicine
Apple’s ResearchKit
MDedge Family Medicine
GI symptoms common in Parkinson’s disease and related disorders
MDedge Family Medicine